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Abstract
Background: In France, roughly 40,000 HIV-infected persons are unaware of their HIV infection. Although previous studies
have evaluated the cost-effectiveness of routine HIV screening in the United States, differences in both the epidemiology of
infection and HIV testing behaviors warrant a setting-specific analysis for France.
Methods/Principal Findings: We estimated the life expectancy (LE), cost and cost-effectiveness of alternative HIV screening
strategies in the French general population and high-risk sub-populations using a computer model of HIV detection and
treatment, coupled with French national clinical and economic data. We compared risk-factor-based HIV testing (‘‘current
practice’’) to universal routine, voluntary HIV screening in adults aged 18–69. Screening frequencies ranged from once to
annually. Input data included mean age (42 years), undiagnosed HIV prevalence (0.10%), annual HIV incidence (0.01%), test
acceptance (79%), linkage to care (75%) and cost/test (J43). We performed sensitivity analyses on HIV prevalence and
incidence, cost estimates, and the transmission benefits of ART. ‘‘Current practice’’ produced LEs of 242.82 quality-adjusted
life months (QALM) among HIV-infected persons and 268.77 QALM in the general population. Adding a one-time HIV screen
increased LE by 0.01 QALM in the general population and increased costs by J50/person, for a cost-effectiveness ratio (CER)
of J57,400 per quality-adjusted life year (QALY). More frequent screening in the general population increased survival, costs
and CERs. Among injection drug users (prevalence 6.17%; incidence 0.17%/year) and in French Guyana (prevalence 0.41%;
incidence 0.35%/year), annual screening compared to every five years produced CERs of J51,200 and J46,500/QALY.
Conclusions/Significance: One-time routine HIV screening in France improves survival compared to ‘‘current practice’’ and
compares favorably to other screening interventions recommended in Western Europe. In higher-risk groups, more frequent
screening is economically justifiable.
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An estimated 6,500 to 7,600 new cases of HIV were diagnosed
every year between 2003 and 2008 in France, where the overall
population size is 63 million. In 2008, 60% of those new diagnoses
were among heterosexual men and women [1]. Although HIV
tests are free of charge in France and current HIV testing rates
among non-blood donors rank second in Europe at 5 million tests
per year [2,3], roughly 40,000 of an estimated 106,000–134,000
HIV-infected people throughout the country remain unaware of
their infection [4]. Furthermore, 36% of HIV-infected patients in
France present to care with CD4 counts ,200/ml and/or AIDS-
related symptoms [5].
Most European countries currently recommend risk-factor-
based testing, wherein physicians offer HIV tests at the patient’s
request or when s/he is observed to be at high risk of infection [6].
Several recent studies in the United States, however, have shown
that routine, voluntary HIV screening is clinically effective and
cost-effective compared to ad hoc practices of HIV testing [7,8].
Although challenges to implementation remain [9], the US
Department of Health and Human Services recommends routine
screening countrywide [10]. Given the lower prevalence of
undiagnosed HIV and higher rates of non-routine HIV testing
in France, however, it is not possible to extrapolate results from the
United States to France.
Recognizing the need to reconsider the approach to HIV testing
in France, we estimate the survival benefits, costs and cost-
effectiveness of routine, voluntary HIV screening in the French
general population and important sub-populations.
Methods
Analytic overview
We used a computer-based simulation model of HIV detection
and treatment [7,8,11,12] to estimate the changes in life
expectancy, quality-adjusted life expectancy, and cost associated
with a population-wide program of routine HIV screening once,
every five years, and annually in adults aged 18–69. We also
considered targeted screening in three sub-populations (men who
have sex with men [MSM], injection drug users [IDU] and
heterosexuals), as well as French Guyana, the French administra-
tive region with the highest rates of HIV prevalence and delayed
access to care [5,13]. Model input parameters were derived
primarily from French national data and the medical literature.
Outcome measures were assessed from a modified societal
perspective and life expectancy, quality-adjusted life expectancy,
and costs (2007 J) were discounted at a rate of 3% per annum
[14].
Model overview
Disease Module. The Cost-Effectiveness of Preventing
AIDS Complications (CEPAC) model is a widely published first-
order state-transition Monte Carlo simulation of the natural
history, clinical management, outcomes, and costs of HIV disease
(see Appendix S1) [11,12,15]. Each HIV-infected patient is
followed from model entry until death. Monthly transitions
between ‘‘health states’’ describe the natural history of disease.
Disease progression is determined by CD4 count, HIV RNA level,
and history of opportunistic diseases (Appendix S1, Table A1).
ART can alter these outcomes by reducing HIV RNA, increasing
CD4 counts, and providing independent protection from
opportunistic diseases [16]. ART and opportunistic disease
prophylaxis can also lead to adverse events, resulting in
increased costs and morbidity. Morbidity is incorporated in a
single outcome measure which adjusts survival for quality of life
[11,12,17,18].
Screening Module. The Screening Module captures HIV
prevalence and incidence and determines entry into the Disease
Module (see Appendix S1) [7,8]. HIV-infected patients can be
diagnosed in three ways. First, patients can present to care with an
AIDS-defining opportunistic disease. Second, they can be
diagnosed via existing programs of risk-factor-based, non-routine
HIV testing, hereinafter referred to as ‘‘current practice.’’ In the
‘‘current practice’’ scenario, we assume a constant rate of HIV
diagnosis over both time and any expanded HIV screening
intervention. Third, they can be diagnosed via an expanded
program of routine screening. We assume that test sensitivity and
specificity, follow-up, and linkage to care are all imperfect in the
routine screening program.
The Screening Module conveys information on each patient to
the Disease Module, which determines when patients who have
been diagnosed and linked to care become eligible for clinic visits,
ART and opportunistic disease prophylaxis [19]. Patients only
initiate care once their HIV infection has been diagnosed. The
delay from HIV infection to diagnosis affects the severity of disease
(CD4 count) at treatment initiation.
Disease Module inputs
Cohort characteristics and disease progression. The
demographics of the simulated cohort represent the 18–69 year-
old population in France [20]. Mean age was 42 years and 50% of
participants were male (Table 1) [20]. CD4 count-stratified
opportunistic disease incidence and mortality rates were derived
from two French clinical cohorts [21].
Treatment. As recommended by French national guidelines,
detected patients initiated ART at CD4 counts ,350/mlo ra n
observed severe opportunistic disease [19]. Patients received up to
six sequential ART regimens. These were switched upon virologic
failure, defined as an observed increase in detectable HIV RNA
over two consecutive months. Clinic visits, CD4 counts, and HIV
RNA tests occurred every three months, as well as in the month of
any opportunistic disease [19]. ART and opportunistic disease
prophylaxis efficacies were derived from published randomized
controlled trials (Table 1) [22–25].
Costs and quality of life. The direct costs of routine medical
care and opportunistic disease treatment were derived from the
French Tourcoing AIDS Reference clinical cohort [26]. Although
the economic cost data reported in our paper are the result of a
unit costing analysis conducted on 2005 data, French health care
prices have remained relatively stable in the intervening period.
We used the ‘‘Health’’ component of the French Consumer Price
Index to convert these costs to 2007. Prophylaxis and
antiretroviral medication costs are from the pharmacy records of
the Tourcoing Hospital in France. Quality of life weights by health
state are from the HIV Cost and Services Utilization Study and
other published studies (Appendix S1, Table A1) [27,28].
Screening Module inputs
Prevalence and incidence. We used two methods to
estimate the prevalence of undiagnosed HIV in France in 2005.
First, we employed a ‘‘back-calculation’’ approach – using
published estimates of observed AIDS cases, the HIV-to-AIDS
incubation time, and ART efficacy [29] – to estimate the number
of HIV-infected persons in France in 2000 at 88,200 [29,30].
Second, we extrapolated from non-correlated epidemiological
estimates of HIV prevalence in specific groups [30]. The most
recent weighted-average estimate of the number of HIV-infected
persons in France using this ‘‘direct’’ method, from 1997, is
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in 2005, we added 7,360 new HIV diagnoses per year [31] and
subtracted 1,700 HIV-related deaths per year [32]. We
determined that in 2005, 116,500–151,100 people in France
were living with HIV, of whom only 77,400 were in care [33].
With the back-calculation approach, the 2005 prevalence of
undiagnosed HIV infection was 0.10%, while with the direct
method it was 0.18%. We used the more conservative estimate of
Table 1. Summary of input parameters for a model of routine, voluntary HIV screening in France.
Variable Baseline value Range Source
Age, years 42 20 – 42 [20]
Male sex, % of patients 50 --- [20]
Prevalence of undiagnosed HIV, %
General population 0.10 0.05 – 5.0 [29–34,42,62]
Injection drug users 6.17 6.17 – 9.25 [30,42,62]
French Guyana
a 0.41 --- [13]
Men who have sex with men 1.70 0.85 – 1.70 [30,42,62]
Heterosexual population 0.04 --- [30,42,62]
Annual incidence, /100PY
General population 0.01 0.01– 0.13 [31,34]
Injection drug users 0.17 --- [31,34]
French Guyana 0.35 --- [13,31]
Men who have sex with men 0.99 --- [31,34]
Heterosexual population 0.01 --- [31,34]
Mean CD4 count at HIV care initiation in the ‘‘current practice’’ scenario, cells/ml (SD)
General population 372 (257) --- [42]
Injection drug users 342 (180) --- [42]
French Guyana 347 (229) --- [42]
Men who have sex with men 442 (289) --- [42]
Heterosexual population 357 (252) --- [42]
Monthly probability of diagnosis and linkage to care via non-routine HIV test, % 2.8 0 – 8.3 [42]
Rate of test acceptance, % 79 20 – 90 [36]
Rate of return for results and linkage to care, % 75 20 – 90 [37]
Costs, 2007 J
Test (pre-test counseling + blood draw + ELISA) 43 11 – 85 [38]
Confirmatory test (blood draw + Western Blot) 53 --- [38]
Post-test linkage and counseling costs for HIV+ patients 22 --- [63]
Secondary HIV transmission rate according to plasma viral load (copies/ml), /100PY
$50,000 9.0 4.5 – 18.1 [40]
10,000 – 49,999 8.1 4.1 – 16.2 [40]
3,500 – 9,999 4.2 2.1 – 8.3 [40]
400 – 3,499 2.1 1.0 – 4.1 [40]
,400 0.2 0.1 – 0.3 [40]
ART efficacy at 48 weeks, % HIV RNA ,400 copies/ml (mean increase in CD4 count, cells/ml)
TDF/FTC + EFV 81 (190) --- [22]
ATV/r + 2 NRTIs 70 (110) --- [23]
3rd-line
b 58 (121 ) 60 – 90 [23]
4th-line
b 65
c (102
c) 50 – 70 [24]
5th-line
b 40
c (121) 20 – 50 [25,47]
6th-line
b 12 (45) 10 – 40 [25]
PY: person-year; SD: standard deviation; ART: antiretroviral therapy; TDF: tenofovir; FTC: emtricitabine; EFV: efavirenz; ATV/r: ritonavir-boosted atazanavir; NRTI:
nucleoside reverse transcriptase inhibitor.
aThe method used to derive the prevalence of HIV in French Guyana is different than the method used for the French general population and all other sub-populations.
bOnce patients start third-line therapy, genotype tests generally determine individualized regimens. ART lines 3–6 are therefore modeled as generic regimens with wide
ranges of efficacy, represented by various recent studies.
cat 24 weeks.
doi:10.1371/journal.pone.0013132.t001
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number of new HIV diagnoses in 2005, the incubation time from
HIV infection to AIDS, and the mean delay from infection to
initiation of care [20,34], HIV incidence in the general population
was estimated at 0.01/100 person-years (PY) (Table 1).
The prevalence of undiagnosed HIV in sub-populations and
French Guyana ranged from 0.04% among heterosexuals to
6.17% among IDU. Incidence ranged from 0.01/100PY among
heterosexuals to 0.99/100PY among MSM (see Appendix S1).
Delay from infection to HIV care. In 2005, mean CD4
count at initiation of HIV care under ‘‘current practice’’
conditions in French Hospitals, which included routine clinic
visits and laboratory monitoring, was 372/ml (standard deviation,
257/ml), and 25% of patients initiated care at CD4 counts ,200/
ml (interquartile range, 200–500) (Table 1) [35]. We used the
Screening and Disease Modules to estimate the mean time from
HIV infection to initiation of HIV care in the ‘‘current practice’’
scenario, and found a mean delay from infection to linkage of 36
months, or a 2.8% monthly probability of non-routine testing,
diagnosis and HIV care initiation (Table 1). This rate of non-
routine HIV testing includes imperfect test results as well as
imperfect linkage to care. The delay from HIV infection to
diagnosis in the HIV screening scenarios was determined by the
model and depended on screening frequency. In our analysis,
when patients were offered routine HIV tests, an estimated 79% of
patients accepted them and 75% of those who tested positive
effectively linked to care [36,37]. We assumed that patients who
linked to care did so in the month after detection.
Test characteristics and frequencies. A routine HIV test,
which included pre-test counseling, a blood draw, and a fourth-
generation enzyme-linked immunosorbent assay (ELISA) test, cost
J43 [19,38]. Reactive tests were followed by a physician consult, a
blood draw, and a confirmatory Western blot analysis (Table 1).
The physician consult included post-test counseling and linkage to
care (J22). Quality of life was reduced by 32% for seven days after
a positive ELISA test, to account for the anxiety related to waiting
for confirmation or refutation of a reactive test (Appendix S1,
Table A1) [39]. We conducted extensive sensitivity analyses on
these parameters.
Secondary transmission
Recognizing that ART reduces infectivity by lowering HIV
RNA levels [40], we determined the impact of earlier HIV
diagnosis on secondary transmission by estimating the number of
secondary cases per infected individual in each testing scenario (see
Appendix S1). We used model output to obtain the number of life-
months that treated and untreated patients spent in each of the
model’s HIV RNA strata. These values were multiplied by
international data on transmission by HIV RNA level to obtain
the total number of secondary transmissions [40]. Secondary
transmission rates ranged from 0.2/100PY at HIV RNA levels
,400 copies/ml to 9.0/100PY at HIV RNA levels .50,000
copies/ml (Table 1). We varied these input parameters in
sensitivity analysis to account for the impact of HIV status
knowledge on high-risk behavior.
Each secondary infection was assigned a survival loss and an
economic cost. These were derived by comparing model-based
estimates of quality-adjusted survival and lifetime medical costs
among HIV-infected persons, assuming current standards of care
and HIV-specific quality of life weights, to quality-adjusted
survival and lifetime medical costs among HIV-uninfected persons
[41–43]. In the ‘‘current practice’’ scenario, mean loss per
secondary infection was 20.41 quality-adjusted life-months
(QALM), discounted to the time of infection, and the mean
additional cost of one secondary HIV infection was J100,150. We
accounted for delays from primary to secondary HIV infection
and from secondary HIV infection to diagnosis [7,44].
Sensitivity analyses
We performed extensive sensitivity analyses on estimates of
undiagnosed HIV prevalence, incidence, mean initial age, test
acceptance, linkage to care, non-routine testing rates, HIV
treatment costs, and the quality of life decrement associated with
a reactive test (Figures 1 and 2). We also varied the cost of the HIV
screening program. In addition to varying the cost of the HIV test,
we added the fixed cost of putting in place new routine screening
programs throughout France. These start-up costs would mainly
consist of training general practitioners. We assumed that 80% of
the 103,916 general practitioners in France would participate in a
two-day training course, each comprising 20 physicians [45]. As
part of the training, physicians would receive J330 per day and
instructors would receive J1,500 per course; overhead costs would
be J2,000 per course [46]. Overall start-up costs were thus
estimated at J69,415,900. When we considered that 10 to 20
million people – 25–50% of the targeted population – would
receive HIV tests, program start-up costs added J3.47–6.94 to the
per person cost of routine HIV screening. Finally, we varied ART
initiation criteria and ART regimen efficacies, and considered a
zero probability of transmission in patients with HIV RNA ,500
copies/ml and increases in high-risk behavior upon HIV diagnosis
and ART initiation (Appendix S1, Table A3).
Ethics Statement
The medical ethics review committees of the contributing
hospitals exempted this research from institutional review board
approval, because all input data were obtained from secondary
sources, we did not have access to any patient identifiers, and there
was no direct contact with any human subjects.
Results
Base case analysis
In the ‘‘current practice’’ scenario, mean CD4 count at
diagnosis was 308/ml among prevalent cases and 370/ml overall;
25% of patients were diagnosed after presenting to care with an
AIDS-defining opportunistic disease (Appendix S1, Table A2).
Mean discounted life expectancy for HIV-infected patients was
242.82 QALM (419.00 undiscounted QALM) (Table 2). When we
took secondary HIV cases into account, mean discounted life
expectancy in the general population was 268.77 QALM (479.12
undiscounted QALM) and per person discounted costs were
J1,290.
When we added a one-time routine HIV test to ‘‘current
practice,’’ mean CD4 count at diagnosis increased to 362/ml
among prevalent cases and 379/ml overall. The proportion of
patients diagnosed with HIV after presenting to care with an
AIDS-defining opportunistic disease decreased to 23% (Appen-
dix S1, Table A2). Secondary cas e sa tt e ny e a r sd e c r e a s e db y
7.5% (Table 2). One-time routine HIV screening conferred an
additional 1.27 discounted QALM per HIV-infected person
(2.18 undiscounted QALM) and an additional 0.01 QALM/
person in the general population (0.02 undiscounted QALM), at
an additional cost of J50/person. When we did not account for
the impact of HIV screening on secondary transmission, the
cost-effectiveness of adding one routine HIV test to ‘‘current
practice’’ was J61,100 per quality-adjusted life-year (QALY).
When we combined the favorable effects of screening on HIV
transmission with individual-level life expectancies and costs, the
Routine HIV Testing in France
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the frequency of screening to once every five years in the general
population cost J332,200/QALY compared to one-time
routine HIV screening. Screening annually further increased
costs but did not produce any health benefits, because the
quality of life losses associated with false-positive tests offset any
survival gains.
Sensitivity analyses
When we kept incidence constant, variations in the prevalence
of undiagnosed HIV infection had an impact on results (Figure 1).
When the prevalence of undiagnosed HIV decreased from 0.10%
to 0.05%, the cost-effectiveness ratio of one-time routine HIV
screening compared to ‘‘current practice’’ increased to J161,000/
QALY. When we increased the prevalence of undiagnosed HIV in
France to 0.18% (from the ‘‘direct method’’), the cost-effectiveness
of a one-time routine HIV test compared to ‘‘current practice’’
was J44,400/QALY.
We performed a similar analysis to determine the cost-
effectiveness of routine HIV screening among IDU, MSM and
heterosexuals, as well as in French Guyana (Figure 1, Table 3).
Among IDU and in French Guyana, annual screening led to cost-
effectiveness ratios of J51,200 and J46,500/QALY, respectively,
compared to screening every 5 years. Adding a one-time routine
HIV test to current practice among MSM increased life
expectancy by 0.08 QALM and increased mean costs by J210,
leading to a cost-effectiveness ratio of J32,400/QALY compared
to current practice. Screening annually led to higher survival and
costs, but a less favorable incremental cost-effectiveness ratio
(J97,200/QALY) compared to a one-time HIV test. Among
heterosexuals, adding a one-time routine HIV test to current
practice led to a cost-effectiveness ratio of J145,200/QALY.
Screening annually was more expensive and produced no health
benefit.
We evaluated changes in the cost-effectiveness of one-time,
population-wide, routine HIV screening when we varied major
Figure 1. Effect of undiagnosed HIV prevalence on the cost effectiveness a one-time routine, voluntary HIV test vs. ‘‘current
practice’’, with base case incidence. Incidence rates are as follows: general population, 0.01/100PY; heterosexuals, 0.01/100PY; French Guyana,
0.35/100PY; MSM, 0.99/100PY; and IDU, 0.17/100PY. MSM: men who have sex with men; IDU: injection drug users; PY: person-year.
doi:10.1371/journal.pone.0013132.g001
Figure 2. Sensitivity analyses: One-time routine, voluntary HIV test vs. ‘‘current practice’’ in the general population, with base case
prevalence and incidence. The width of the bar indicates the variation in the incremental cost-effectiveness ratio associated with alternative
parameter values for that input. The numbers to the right and left of the bars indicate the lower- and upper-bounds of the ranges used in sensitivity
analyses.
doi:10.1371/journal.pone.0013132.g002
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(Figure 2).VariationsinHIVtestcostand ratesofundiagnosedHIV
prevalence, linkage to care and non-routine testing had the largest
impact on results. If the quality of life decrement associated with
waiting for confirmation or refutation of a reactive test decreased, a
one-timeHIVtest inthegeneralpopulation becamemore attractive
compared to ‘‘current practice.’’ Finally, when we reduced the
mean age of the cohort but maintained the base case prevalence,
one-time routine HIV screening became more cost-effective.
New HIV incidence rates, which account for very recent HIV
infections, were recently derived for the French general population
and sub-populations [47]. These estimates were similar to ours and
did not have an impact on our main results. Results also remained
robust to variations in HIV test acceptance rate, HIV test
sensitivity and specificity, ART efficacy and initiation criteria,
HIV screening start-up costs, and secondary transmission rates
(Appendix S1, Table A3).
Discussion
We found that a one-time routine, voluntary HIV test in the
French general population decreases the delay from HIV infection
to diagnosis, increases mean CD4 count at diagnosis, improves
survival among HIV-infected patients, reduces secondary infec-
tions at ten years, and achieves cost-effectiveness ratios that are
viewed as acceptable by French standards [48]. More frequent
screening is economically justifiable in specific sub-populations
that are at higher risk for HIV, such as MSM, IDU, and the
population of French Guyana.
This study is the first to evaluate the cost-effectiveness of routine
HIV screening in Europe. Previous studies have found the cost-
effectiveness of one-time routine HIV screening in the United
States to range from less than $50,000/QALY (J41,400/QALY
in 2007 J) in health care settings with undiagnosed HIV
prevalence rates .0.05% [49], to $60,700/QALY (J50,200/
QALY, in 2007 J) in populations with an undiagnosed HIV
prevalence of 0.10% [7,8]. Several factors may lead to higher cost-
effectiveness ratios in the European setting, including higher rates
of risk-factor-based, non-routine HIV testing, higher CD4 counts
at diagnosis, and fewer patients presenting to care with AIDS-
defining opportunistic diseases [42,50]. Still, roughly one-third of
HIV-infected individuals in France are unaware of their HIV
status [4] and the prevalence of undiagnosed HIV is estimated at
0.10%. Recent evidence shows that delayed diagnosis in France is
more common among patients at a perceived low risk of infection,
such as heterosexuals and older individuals [5], because current
HIV testing strategies specifically target high-risk groups, namely
MSM and IDU. Although HIV screening in France is slightly less
cost-effective than in the US, primarily due to the lower
prevalence of undiagnosed HIV in France, one-time HIV
screening compares favorably to other screening interventions
recommended in Western Europe (Table 4) [51–55].
The cost-effectiveness of routine HIV screening estimated in this
study may apply to other European countries. One-time HIV
screening was associated with favorable cost-effectiveness ratios
when undiagnosed HIV prevalence rates were $0.10%. Although
undiagnosed HIV prevalence varies by region, several European
countries have reported that HIV-infected individuals frequently
present to care with AIDS-defining symptoms [5,56–59]. Recent
studies have estimated that 30% of HIV-infected individuals in the
European Union remain undiagnosed, with proportions ranging
from 12–20% in Denmark, Norway and Sweden, to over 50% in
Table 2. Routine, voluntary HIV screening in the French general population.
Variable
‘‘Current
practice’’
‘‘Current
practice’’ and
screen once
‘‘Current practice’’ and
screen every 5 years
‘‘Current practice’’
and screen annually
Reduction in secondary HIV cases, %
a -- 7.5 10.3 17.8
HIV-infected persons
Mean undiscounted life expectancy, months 451.46 453.84 456.82 459.87
Mean undiscounted quality-adjusted life expectancy, QALM 419.00 421.18 423.97 426.83
Mean discounted life expectancy, months 258.34 259.73 260.85 262.14
Mean discounted quality-adjusted life expectancy, QALM 242.82 244.09 245.14 246.36
Mean discounted lifetime costs per person, 2007 J 134,880 138,320 142,080 148,190
Population
Mean undiscounted life expectancy, months 479.13 479.15 479.17 479.20
Mean undiscounted quality-adjusted life expectancy, QALM 479.12 479.14 479.16 479.17
Mean discounted life expectancy, months 268.83 268.84 268.85 268.86
Mean discounted quality-adjusted life expectancy, QALM 268.77 268.78 268.78 268.78
Mean discounted lifetime costs per person, 2007 J 1,290 1,340 1,500 2,130
Incremental cost-effectiveness
b
Only 1u HIV cases, J/QALY -- 61,100 443,700 Dominated
c
1u and 2u HIV cases, J/YLS -- 51,500 215,500 737,000
1u and 2u HIV cases, J/QALY -- 57,400 332,200 Dominated
c
QALM: quality-adjusted life-month; QALY: quality-adjusted life-year; YLS: year of life saved.
aReduction in secondary cases is compared to ‘‘current practice’’ at 10 years.
bIncremental cost-effectiveness = (difference in cost) / (difference in quality-adjusted life expectancy), where the comparator is always the next smallest, not
dominated, alternative.
cA dominated strategy has a higher cost and an equal or lower quality-adjusted life expectancy than some combination of other strategies.
doi:10.1371/journal.pone.0013132.t002
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or Switzerland where the prevalence of diagnosed HIV is equal to
or higher than in France [61], it is likely that the prevalence of
undiagnosed HIV is above 0.10% and that rates of non-routine
HIV testing and CD4 counts at diagnosis are no higher than in
France.
Variations in several parameters led to important results. First,
the frequency of routine HIV screening was strongly dependent on
the targeted sub-population. More frequent screening was
associated with favorable cost-effectiveness ratios among sub-
populations with higher HIV incidence rates, such as IDU and
French Guyana. The cost-effectiveness of annual screening in
MSM was higher than in IDU and French Guyana, because non-
routine testing rates and CD4 counts at HIV diagnosis in this
group are already high. Second, the attractiveness of routine
screening hinges on earlier and more frequent presentation to care
among persons who test positive for HIV. Interventions to
improve linkage to care should be implemented alongside routine,
voluntary HIV screening, particularly in marginalized groups
known to be at risk for delayed presentation to care and loss to
Table 3. Routine, voluntary HIV screening among French sub-populations
a.
Variable
‘‘Current
practice’’
‘‘Current
practice’’ and
screen once
‘‘Current practice’’ and
screen every 5 years
‘‘Current practice’’
and screen annually
Injection drug users (undiagnosed prevalence, 6.17%; incidence, 0.17/100 PY)
Mean undiscounted life expectancy, months 452.71 453.79 454.37 455.21
Mean discounted quality-adjusted life expectancy, QALM 258.62 259.30 259.51 259.88
Mean discounted lifetime costs per person, 2007 J 27,480 29,240 29,960 31,540
Incremental cost-effectiveness, J/QALY -- 30,900 41,200 51,200
French Guyana (undiagnosed prevalence, 0.41%; incidence, 0.35/100 PY)
Mean undiscounted life expectancy, months 455.71 455.77 457.11 458.41
Mean discounted quality-adjusted life expectancy, QALM 262.45 262.50 262.91 263.28
Mean discounted lifetime costs per person, 2007 J 21,980 22,170 23,100 24,510
Incremental cost-effectiveness, J/QALY -- Dominated
b 28,800 46,500
Men who have sex with men (undiagnosed prevalence, 1.70%; incidence, 0.99/100 PY)
Mean undiscounted life expectancy, months 391.68 391.80 391.94 392.44
Mean discounted quality-adjusted life expectancy, QALM 241.48 241.56 241.58 241.69
Mean discounted lifetime costs per person, 2007 J 57,530 57,750 58,000 58,840
Incremental cost-effectiveness, J/QALY -- 32,400 Dominated
b 97,200
Heterosexual population (undiagnosed prevalence, 0.04%; incidence, 0.01/100 PY)
Mean undiscounted life expectancy, months 479.82 479.83 480.06 479.86
Mean discounted quality-adjusted life expectancy, QALM 268.98 268.98 268.98 268.98
Mean discounted lifetime costs per person, 2007 J 580 630 770 1,400
Incremental cost-effectiveness, J/QALY -- 145,200 963,000 Dominated
b
PY: person-year; QALM: quality-adjusted life-month; QALY: quality-adjusted life-year
aAll results incorporate the favorable effects of routine HIV screening on secondary HIV transmission. The cost-effectiveness results shown are not calculable, due to
rounding.
bA dominated strategy has a higher cost and an equal or lower quality-adjusted life expectancy than some combination of other strategies.
doi:10.1371/journal.pone.0013132.t003
Table 4. Cost-effectiveness of common and accepted screening interventions recommended in Europe.
Screening programs Cost-effectiveness
a Country of analysis Source
Cervical cancer screening every 5 years, women aged 25–65 years J2,200/YLS France [51]
Rectal cancer screening by fecal occult blood test every 2 years, men and women
aged 50–74 years
J3,700/YLS France [52]
Breast cancer screening every 2 years by mammogram, women aged 50–65 years J23,300/YLS France [53]
Annual Chlamydia screening, men and women aged ,25 years
b J43,100 – 318,500/QALY
a England [54]
One-time hepatitis C screening and treatment, prisoners J86,800/QALY England/Wales [55]
One-time hepatitis C screening and treatment, prisoners aged .35 years J203,100/QALY England/Wales [55]
YLS: years of life saved; QALY: quality-adjusted life-year.
aAll costs updated to 2007 J.
bCost-effectiveness varies depending on the probability of pelvic inflammatory disease after Chlamydia infection.
doi:10.1371/journal.pone.0013132.t004
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population-level data we employed to model secondary HIV
transmission may under-represent rates of infection in high-risk
sub-populations. While we deliberately chose conservative input
values to understate our cost-effectiveness findings, sensitivity
analysis revealed that secondary transmission rates had a smaller
impact on results than anticipated. This is because test acceptance
and linkage to care rates were imperfect, ART initiation was not
immediate, ART failure could occur as a result of non-adherence
and/or toxicity, and results were discounted for the passage of
time to secondary infection.
This analysis has several limitations. The CEPAC model
combines data from multiple sources and relies on various
assumptions to estimate the long-term benefits of alternative
routine HIV screening strategies. First, undiagnosed HIV
prevalence and incidence rates were estimated from back-
calculations [30,34]. Second, in the absence of other data, the
2.8% monthly probability of diagnosis and linkage via non-routine
testing was estimated from reported CD4 counts at initiation of
care in France [35]. Third, we assumed that the anxiety associated
with waiting for confirmation or refutation of a reactive HIV test
in France was similar to the US [39]. Fourth, we were not able to
evaluate the cost-effectiveness of routine HIV screening in
immigrant populations, for whom HIV prevalence and incidence
rates are high, because data on this sub-population are scarce.
Fifth, although we did account for the effect of HIV RNA levels on
transmission, we did not incorporate the behavioral effects of
counseling or the role of ART in prolonging infectious survival
and possibly increasing sexual risk-taking. However, most of these
assumptions were largely conservative with respect to the benefits
of routine HIV screening.
New strategies that encourage earlier HIV testing in France
are needed. This study suggests that one-time routine, voluntary
HIV screening should be implemented on a population-wide
basis in France. More frequent screening is warranted in sub-
populations with high HIV prevalence and incidence rates. These
screening strategies will only be successful if efforts to increase
both the acceptability of HIV screening and linkage to care are
implemented.
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